Figures & data
Figure 1 Legend: Simplified schema depicting current therapies targeting CD22 in B-cell malignancies. (A) Naked antibody; (B) Antibody-drug conjugate; (C) Radioimmunoconjugate; (D) Bispecific antibody/bispecific T-cell engager; (E) Chimeric antigen receptor (CAR)-T cell; (F) Bispecific CAR-T cell; (G) Tandem bispecific CAR-T cell. Abbreviations: 90Y, Yttrium-90. Figure created with BioRender.com.
![Figure 1 Legend: Simplified schema depicting current therapies targeting CD22 in B-cell malignancies. (A) Naked antibody; (B) Antibody-drug conjugate; (C) Radioimmunoconjugate; (D) Bispecific antibody/bispecific T-cell engager; (E) Chimeric antigen receptor (CAR)-T cell; (F) Bispecific CAR-T cell; (G) Tandem bispecific CAR-T cell. Abbreviations: 90Y, Yttrium-90. Figure created with BioRender.com.](/cms/asset/846ed629-aea1-4113-8fdd-8345015571f0/ditt_a_12166760_f0001_c.jpg)
Table 1 Selected Ongoing Studies Investigating CD22 Targeted Therapies in B-Cell Malignancies